Objective: To evaluate the efficacy of prazosin for posttraumatic stress disorder (PTSD)-related nightmares in veterans and to analyze subgroup benefit/risk to guide prescribing.
Methods: Patients with a previous prescription for prazosin between 1 June 2007 and 30 June 2017 were collected from the institution's electronic records. Efficacy (including nightmare frequency, and clinical PTSD rating scales) and safety (including blood pressure) data were retrospectively analyzed.
Results: Eighty-four patients were included in the analysis. The primary outcome, item 2 of the PTSD checklist, decreased from 4.00 to 3.19 (on a scale of 1-5), which was statistically significant (p < 0.05). Nightmare frequency was found to have a statistically significant decrease from four to two times per week on average (p = 0.00002, 95% CI 2.36 [1.39-3.33]). Of the patients who reported the greatest response (n = 23), 91% (n = 21) were on an antidepressant and 61% (n = 14) were receiving concurrent psychotherapy. This is compared to 90% (n = 76) and 44% (n = 37) of the total cohort, respectively. No significant differences were found in blood pressure or suicidal ideation (p = 0.58 and p = 0.22, respectively).
Conclusion: Prazosin may be considered as an adjunct option to decrease nightmare frequency in patients already receiving first-line treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/hup.2785 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Doxazosin Immediate Release as a Novel Treatment for Nightmares in Posttraumatic Stress Disorder.
Case Rep Psychiatry
November 2024
Department of Psychiatry, Rowan-Virtua School of Osteopathic Medicine, Stratford, New Jersey, USA.
Article Synopsis
- Nightmares and flashbacks are common symptoms of PTSD that can severely affect daily life.
- Prazosin is often used off-label to treat these symptoms, but its short half-life requires multiple doses throughout the day.
- Doxazosin shows promise as an alternative treatment for PTSD-related nightmares, with a longer half-life and fewer side effects, as demonstrated in three patient cases after prazosin was stopped.
Consequences of Discontinuing Long-Term Drug Treatment in Patients With Heart Failure and Reduced Ejection Fraction.
J Am Coll Cardiol
November 2024
Baylor Heart and Vascular Institute, Dallas, Texas, USA; Imperial College London, London, United Kingdom. Electronic address:
Article Synopsis
- There's uncertainty about the effects of stopping heart failure drugs after long-term use, with four main patterns of withdrawal impact observed.
- Discontinuing some medications can lead to worsening symptoms, while others may show lingering benefits before decline.
- Overall evidence indicates patients often experience significant clinical deterioration shortly after stopping heart failure treatments, highlighting the importance of maintaining consistent drug therapy.
Augmentation with prazosin for patients with depression and a history of trauma: A randomised, double-blind, placebo-controlled study.
Acta Psychiatr Scand
February 2025
Key Laboratory, Huzhou Third Municipal Hospital, Affiliated Hospital of Huzhou University, Huzhou, Zhejiang, China.
Article Synopsis
- - The study explored the effectiveness of low-dose prazosin in improving symptoms of depression in patients with a history of trauma, as conventional antidepressants often have limited success in these cases.
- - Conducted as a randomized, double-blind, placebo-controlled trial with 59 participants, the research assessed changes in depression and anxiety scores over six weeks using standardized rating scales.
- - Results indicated that patients on prazosin experienced significantly better improvements in symptoms compared to those on placebo after 4 and 6 weeks, with similar rates of adverse reactions in both groups.
Examination of the antiallodynic effect of rosmarinic acid in neuropathic pain and possible mechanisms of action.
Neurosci Lett
November 2024
Department of Pharmacology, Faculty of Pharmacy, Anadolu University, 26470 Eskisehir, Turkey. Electronic address:
This study aimed to explore the potential antiallodynic effects of rosmarinic acid, a natural antioxidant with a demonstrated safety profile across a broad dose range. Using a chronic constriction injury-induced neuropathic pain model, the impact of rosmarinic acid on allodynia was investigated. Furthermore, the involvement of adrenergic and opioidergic mechanisms in its activity was assessed.
View Article and Find Full Text PDFIdentifying mitigating strategies for endothelial cell dysfunction and hypertension in response to VEGF receptor inhibitors.
Clin Sci (Lond)
September 2024
Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA, U.S.A.
Vascular endothelial growth factor receptor inhibitors (VEGFRis) improve cancer survival but are associated with treatment-limiting hypertension, often attributed to endothelial cell (EC) dysfunction. Using phosphoproteomic profiling of VEGFRi-treated ECs, drugs were screened for mitigators of VEGFRi-induced EC dysfunction and validated in primary aortic ECs, mice, and canine cancer patients. VEGFRi treatment significantly raised systolic blood pressure (SBP) and increased markers of endothelial and renal dysfunction in mice and canine cancer patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!